Health ❯Healthcare ❯Pharmaceuticals

Weight Loss Drugs

Zepbound Wegovy Mounjaro Tirzepatide Ozempic GLP-1 Receptor Agonists GLP-1 Medications Semaglutide Clinical Trials GLP-1 Agonists Novo Nordisk GLP-1 Therapies Eli Lilly and Novo Nordisk Medicare and Medicaid Coverage GLP-1 Drugs Bimagrumab GLP-1 Injections Ozempic and Mounjaro Long-term Effects Ozempic and Tirzepatide Eli Lilly vs Novo Nordisk Mounjaro (Tirzepatide) Hims & Hers Health, Inc. Demand and Supply Issues Eli Lilly's Orforglipron Patient Management Mounjaro and Zepbound GLP-1 Compounds Eli Lilly Zepbound Compounded Semaglutide Eli Lilly Ozempic and Wegovy GLP-1 Class Obesity Treatment GLP-1 Receptor Analogs Compounded Medications CagriSema GLP-1 Treatments Eye Health Medi-Cal Coverage Wegovy and Mounjaro Zepbound vs Wegovy

Costco to Offer Ozempic and Wegovy for $499 a Month to Self-Pay Members Nationwide

The partnership with Novo Nordisk expands access to FDA-approved semaglutide injections at more than 600 Costco pharmacies.

UK ‘Postcode Lottery’ for Weight-Loss Jabs Persists as Generics Line Up for 2026

Mounjaro NHS Rollout Stalls With Fewer Than Half of ICBs Prescribing

Lilly Pauses UK Mounjaro Shipments Ahead of Price Rise as Pharmacies Report Shortages

Eli Lilly Raises 2025 Outlook as Tirzepatide Sales Soar, Orforglipron Misses Marks

Novo Nordisk Shares Slide 65% From Peak as Analysts Flag 40% Upside

Trump Administration Clears Pilot to Cover GLP-1 Weight-Loss Drugs in Medicare, Medicaid

Mounjaro Rivals Trulicity in Cardiovascular Safety and Lowers All-Cause Mortality

Cancer Drugs Reverse Alzheimer’s Pathology in Mice, Advance to Clinical Trials

NHS to Expand GP Prescriptions of Mounjaro for Weight Loss

NHS Weight-Loss Jab Prescriptions Near Three Million as Experts Raise Lifelong Use Concerns

FDA Ends GLP-1 Drug Shortages, Triggering New Pricing and Coverage Moves

‘Ozempic Teeth’ Emerges as a Serious Dental Risk for Weight-Loss Drug Users

WHO to Endorse GLP-1 Weight-Loss Drugs, Calls for Global Access

FDA Seizes Counterfeit Ozempic in U.S. Supply Chain

Hims & Hers Expands Weight-Loss Offerings with New Medications

Novo Nordisk Acquires Chinese Obesity Drug After CagriSema Trial Disappointment

Taxpayer-Funded Weight-Loss Drugs Face Scrutiny Over High Prices

Eli Lilly Expands Zepbound Access with New Doses and Lower Prices

FDA Ends Shortage of Tirzepatide, Restricts Compounded Weight-Loss Drugs